Abstract: 【Abstract】 Childhood psoriasis is an immune-mediated chronic, recurrent, systemic skin disease induced by both genetic and environmental factors （e.g., infection, etc.） and occurring in children aged under 18 years. Its clinical manifestations are complex and vary widely between different types. Because of the special physiological condition of children, more attention should be paid to safety of treatment. Compared with adults, the treatment of psoriasis in children is more challenging due to limited options. For example, the ideal therapeutic dose of systemic drugs, adverse effects of long-term treatment, the choice of drug combination, and the conversion of drugs have not been clarified. Many drugs, including topical and systemic drugs, have not been approved for the treatment of childhood psoriasis. The purpose of this consensus is to standardize the diagnosis and treatment of childhood psoriasis more effectively and scientifically, to guide physicians to timely and effective control of occurrence and development of childhood psoriasis, to improve the quality of life of children and their families, and to help children develop and grow as healthily as possible.

Key words: Psoriasis, Child, Diagnosis, Therapy, Practice guideline